Health Care · Biological Products, (No Diagnostic Substances)

CRDF Cardiff Oncology, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1213037121 filings
Russell 2000

CRDF at a glance

Cardiff Oncology, Inc. (CRDF, SEC CIK 1213037) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as July 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Cardiff Oncology, Inc. (CRDF) reported revenue of $593,000 (down 13.2% from FY2024) and a net loss of $45.9 million. Diluted EPS was -$0.69.
  • As of September 30, 2026, 18 institutional investment managers tracked by SignalX reported holding Cardiff Oncology, Inc. (CRDF) shares worth $10.6 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by PACE GARY W on July 14, 2026 of 687,285 shares at $1.46 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$593K
−13.2% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
18 funds
$10.6M · −5 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes from Form 10-K risk factors for year ended December 31, 2025
  • Carried-forward risks not specified in provided section

Management Discussion & Analysis

  • Quarterly revenue $0.2M vs $0.1M YoY
  • R&D expense $5.0M vs $8.2M YoY, SG&A $4.4M vs $3.9M
  • Best program: 30 mg onvansertib plus FOLFIRI/bev, ORR 72.2% vs 42.1% SoC
  • Cash, equivalents and short-term investments $33.8M at September 30, 2026, operating cash use $33.9M
  • Funding projected through Q3 2027, substantial going-concern doubt and additional capital required

AI summary of the CRDF 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 business update and financial results announced for quarter ended September 30, 2026
  • Full operating and financial details contained in Exhibit 99.1, Cardiff Oncology’s accompanying press release

Item EX-99.1: Item EX-99.1

  • Phase 2 efficacy signal strengthening: median PFS not reached at 30 mg onvansertib plus FOLFIRI/bev versus approximately 11 months for combined SoC arms
  • All remaining patients in the proposed Phase 3 regimen exceeded 21 months on treatment, with longest duration over 29 months
Filed Oct 27, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Chief Medical Officer Roger Sidhu departed October 22, 2026 through a mutually agreed transition
  • Leila Alland appointed interim Chief Medical Officer effective October 23, 2026

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Authorized common shares increased to 300,000,000, expanding potential equity issuance capacity
  • Effective October 22, 2026 upon Delaware filing

Item EX-99.1: Item EX-99.1

  • Leila Alland, MD appointed interim Chief Medical Officer, replacing Roger Sidhu
  • Leadership change arrives before planned Phase 3 launch in first quarter 2027

Item 7.01: Regulation FD Disclosure

  • Dr. Sidhu resigned as Chief Medical Officer, creating a senior clinical leadership transition
  • Dr. Alland appointed interim Chief Medical Officer, providing temporary oversight of clinical development
Filed Oct 22, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Stockholders approved expanding authorized capital from 170 million to 320 million shares
  • Common-stock authorization increased from 150 million to 300 million shares

AI summaries of CRDF 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CRDF

Don't miss the next CRDF filing

  • Alerts as it files. A push when CRDF files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CRDF, by share count.
  • Ask anything. An AI agent that reads every CRDF filing and answers with sources.

CRDF alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
PACE GARY WBuyJul 14, 2026$1.46
Mohindru ManiBuyJul 14, 2026-
Mohindru ManiBuyJul 14, 2026$1.46
PACE GARY WBuyJul 14, 2026-
PACE GARY WBuyJun 18, 2026$1.22
Mohindru ManiBuyJun 18, 2026$1.21
TANNENBAUM RENEE PAJun 11, 2026-
Armitage James OAJun 11, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$683K$593K
Operating Income--$48.7M-$49.0M
Net Income-$41.4M-$45.4M-$45.9M
Op. Margin--7123.1%-8256.3%
Net Margin--6651.7%-7732.0%
Balance Sheet
Total Assets-$97.2M$61.9M
Equity$69.7M$82.9M$45.4M
ROE-59.4%-54.8%-101.0%
Per Share
EPS$-0.93$-0.95$-0.69
Cash Flow
Operating CF--$37.7M-$37.9M
CapEx$582K$80K$44K

Source: XBRL data in Cardiff Oncology, Inc. (CRDF)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CRDF share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CRDF shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202618$10.6M
Q2 202623$11.9M
Q1 202626$22.4M
Q4 202522$40.6M
Q3 202524$28.3M
Q2 202524$48.9M
Q1 202521$31.7M
Q4 202419$33.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 177 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CRDF filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
8-KOct 27, 2026Analysis-
8-KOct 22, 2026Analysis-
8-KSep 14, 2026Analysis-
8-KAug 11, 2026Analysis-
10-QAug 11, 2026Analysis
8-KJul 16, 2026Analysis-
4Jul 16, 2026--
4Jul 16, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
8-KJun 11, 2026Analysis-
8-KJun 3, 2026Analysis
8-KMay 29, 2026Analysis
8-KMay 19, 2026Analysis
8-KMay 14, 2026Analysis
10-QMay 14, 2026Analysis
4Apr 28, 2026--
4Apr 16, 2026--

Related Health Care companies

All Health Care →

CRDF SEC filings: frequently asked questions

Which institutions hold CRDF stock?

As of September 30, 2026, the largest Cardiff Oncology, Inc. (CRDF) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($3.5 million), Pfizer Inc ($3.0 million), BlackRock ($1.1 million), Franklin Resources ($1.0 million), State Street Corp ($392,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CRDF's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Cardiff Oncology, Inc. (CRDF) reported revenue of $593,000 (down 13.2% from FY2024) and a net loss of $45.9 million. Diluted EPS was -$0.69. The figures come from the XBRL data in the 10-K.

What did CRDF report in its latest 8-K?

Cardiff Oncology, Inc. (CRDF) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 business update and financial results announced for quarter ended September 30, 2026.

What are the latest CRDF SEC filings?

Cardiff Oncology, Inc. (CRDF) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on July 16, 2026.

What is CRDF's SEC CIK number?

Cardiff Oncology, Inc. (CRDF)'s SEC Central Index Key (CIK) is 1213037. EDGAR lists every CRDF filing under that number.

Ask anything about CRDF

The research agent reads CRDF's filings, financials, insider trades and 13F holders, then answers with sources.